Expected costs and benefits of SOF/VEL treatment (in INR).
收藏数据链接：
官方服务：
资源简介：
Expected costs and benefits of SOF/VEL treatment (in INR).
应用场景：
创建时间：
2021-07-22
相关数据集
Reduced heart failure-related healthcare costs with Furoscix versus in-hospital intravenous diuresis in heart failure patients: the FREEDOM-HF study - supplementary table
Aim: Compare heart failure (HF) costs of Furoscix use at home compared with inpatient intravenous (IV) diuresis. Patients & methods: Prospective, case control study of chronic HF pat
DataCite Commons2024-05-17 更新100
Potential life years not saved due to lack of access to anti-EGFR tyrosine kinase inhibitors for lung cancer treatment in the Brazilian public healthcare system: Budget impact and strategies to improve access. A pharmacoeconomic study
ABSTRACT BACKGROUND: Lung cancer is the fourth most common cancer in Brazil. In the 2000s, better understanding of molecular pathways led to development of epidermal growth factor receptor (EGFR)-ta
NIAID Data Ecosystem20
Differences in healthcare resource utilization and direct medical costs of patients with rheumatoid arthritis (RA) before and after the use of multiple biologic agents-Switched.
Differences in healthcare resource utilization and direct medical costs of patients with rheumatoid arthritis (RA) before and after the use of multiple biologic agents-Switched.
Figshare2018-07-18 更新10
Crude and adjusted rate ratios of health care resource utilization among different 1LOT groups.
Crude and adjusted rate ratios of health care resource utilization among different 1LOT groups.
Figshare2021-05-26 更新30
Table 1_Efficacy and safety of antiviral treatments for symptomatic COVID-19 outpatients: network meta-analysis and budget impact analysis.docx
IntroductionRemdesivir (RDV) and nirmatrelvir/ritonavir (NRM/RTV) are two antiviral agents for treating outpatient adults with mild to moderate symptomatic COVID-19 at high risk of developing a severe
NIAID Data Ecosystem10
